DW 166HC

Drug Profile

DW 166HC

Alternative Names: 166 holmium chitosan complex; 166 holmium poliglusam; Holmium 166 chitosan; Milican

Latest Information Update: 10 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong Wha
  • Developer Dong Wha Pharmaceutical
  • Class Antineoplastics; Organometallic compounds; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Liver cancer
  • Discontinued Brain cancer; Rheumatoid arthritis

Most Recent Events

  • 10 Feb 2016 DW 166HC is available for licensing as of 10 Feb 2016. www.dong-wha.co.kr
  • 02 Nov 2007 Clinical trials in Brain cancer in South Korea (Intratumoural)
  • 02 Nov 2007 Discontinued - Phase-II for Rheumatoid arthritis in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top